FDA IND clearance enables a phase 1b evaluation of SP16 in chemotherapy-induced pain and peripheral neuropathy, with enrollment planned for mid-2026 at the University of Virginia. Proposed mechanisms ...
ALPHARETTA, Ga., April 15, 2026 (GLOBE NEWSWIRE)-- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“DWTX”, “Dogwood” or “the Company”), a company that focuses on developing new non-opioid medicines to ...
The SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected to commence in the middle of 2026 at the University of Virginia “FDA acceptance of our SP16 IND ...
The SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected to commence in the middle of 2026 at the University of Virginia ALPHARETTA, Ga., April 15, 2026 ...
SP16 is intended to address significant unmet needs in CIPPN, a condition affecting a large portion of chemotherapy patients and often causing long-lasting numbness, tingling, and pain. Dogwood ...
Serpin Pharma receives FDA IND approval for SP16, a novel therapy for chemotherapy-induced peripheral neuropathy. Phase 1b trial initiation planned MANASSAS, VA ...
"FDA acceptance of our SP16 IND filing represents an important step in expanding our pipeline as we advance a second development candidate into the clinic to treat chemotherapy-induced neuropathy and ...
The SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected to commence in the middle of 2026 at the University of Virginia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results